Last checked at 
28 Jul 2020 12:00
Syncona Limited
Result of Annual General Meeting
28 July 2020
At the Annual General Meeting of the Company held today, all Resolutions as set out in the 'Notice of the 2020 Annual General Meeting' dated 25 June 2020 sent to shareholders of the Company (the "Notice") were duly passed.
Resolutions 1 to 14 were proposed as Ordinary Resolutions. Resolution 15 was proposed as a Special Resolution and Resolution 16 was proposed as an Extraordinary Resolution.
Details of the proxy voting results, which should be read alongside the Notice, are noted below:
No | Resolution | For | Discretion | Against | Abstain |
1 | Receive and consider the Annual Audited Financial Statements of the Company for the year ended 31 March 2020, together with the Reports of the Directors and Auditors thereon | 445,660,527 (99.94%) | 11,733 (0.01%) | 242,263 (0.05%) | 5,000 |
2 | Re-appointment of Deloitte LLP (Guernsey Branch) as Auditors | 445,642,529 (99.98%) | 11,733 (0.01%) | 59,979 (0.01%) | 205,283 |
3 | Authorise the Directors to determine the remuneration of the Auditors | 445,902,291 (99.98%) | 11,733 (0.01%) | 500 (0.01%) | 5,000 |
4 | Re-elect Melanie Gee as a Director | 434,255,293 (99.04%) | 11,733 (0.01%) | 4,156,616 (0.95%) | 7,495,882 |
5 | Re-elect Thomas Henderson as a Director | 444,503,100 (99.68%) | 11,733 (0.01%) | 1,397,191 (0.31%) | 7,500 |
6 | Re-elect Rob Hutchinson as a Director | 445,890,567 (99.98%) | 11,733 (0.01%) | 724 (0.01%) | 16,500 |
7 | Re-elect Nigel Keen as a Director | 444,260,836 (99.62%) | 11,733 (0.01%) | 1,639,454 (0.37%) | 7,500 |
8 | Elect Kemal Malik as a Director | 445,899,035 (99.98%) | 11,733 (0.01%) | 1,256 (0.01%) | 7,500 |
9 | Re-elect Nicholas Moss as a Director | 445,899,567 (99.98%) | 11,733 (0.01%) | 724 (0.01%) | 7,500 |
10 | Re-elect Gian Piero Reverberi as a Director | 445,900,291 (99.99%) | 11,733 (0.01%) | 0 | 7,500 |
11 | Re-elect Ellen Strahlman as a Director | 445,900,291 (99.99%) | 11,733 (0.01%) | 0 | 7,500 |
12 | Approve the report on implementation of the Remuneration Policy for Non-Executive Directors | 445,811,513 (99.97%) | 11,733 (0.01%) | 84,928 (0.02%) | 11,350 |
13 | Approve the Company's remuneration policy | 445,809,247 (99.97%) | 11,733 (0.01%) | 84,694 (0.02%) | 13,850 |
No | Resolution | For | Discretion | Against | Abstain |
14 | Authority to allot shares | 443,984,459 (99.56%) | 11,733 (0.01%) | 1,906,318 (0.43%) | 17,014 |
15 | Authorise the Company to purchase its own shares | 445,529,666 (99.92%) | 109,277 (0.02%) | 264,615 (0.06%) | 15,965 |
16 | Disapply pre-emption rights | 425,619,468 (99.96%) | 109,277 (0.03%) | 20,964 (0.01%) | 20,169,815 |
A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.
In accordance with the Listing Rule 9.6.2, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the Financial Conduct Authority via the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
The full text of the resolutions can be found in the Notice, which is available on the Company's website at www.synconaltd.com/investors.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel: +44 (0) 20 3981 7909
Email: investorrelations@synconaltd.com
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
Email: syncona@fticonsulting.com
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com.
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base, which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.